Stiefel, Basilea sign agreement for Toctino
Toctino is used to treat adults with severe chronic hand eczema that is refractory to treatment with potent topical corticosteroids. Under the agreement Stiefel will be responsible for
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The research collaboration will focus on three neglected tropical diseases (NTDs), leishmaniasis, Chagas disease, and sleeping sickness. Astellas drug discovery research senior vice president Shin-ichi Tsukamoto said the